期刊文献+

HLA-G和Fas配体在肾透明细胞癌中的表达及意义 被引量:2

HLA-G and Fas ligand expression in clear cell renal cell carcinoma
在线阅读 下载PDF
导出
摘要 目的:探讨两种免疫抑制分子人类白细胞表面抗原HLA-G和Fas配体(FasL)与经典型肾透明细胞癌(ccRCC)分级和分期的相关性。方法:采用免疫组织化学方法对60例ccRCC标本石蜡切片进行检测,数据由SPSS软件进行统计分析。结果:肿瘤旁正常肾组织中无HLA-G表达;肾癌组织中,40例(66.7%)表达HLA-G,36例(60.0%)表达FasL,31例(51.7%)两者均表达,15例(25.0%)两者均不表达。在同一标本中,肿瘤侵犯脉管或淋巴结后,其HLA-G或FasL表达较原位肿瘤明显增强。统计分析显示HLA-G表达的阳性率和表达强度与肿瘤的分期、分级均呈正相关(P<0.01)。FasL表达的阳性率与肿瘤分级呈正相关(P<0.05),而表达强度与肿瘤分期呈正相关(P<0.01)。结论:ccRCC中HLA-G和FasL的表达与肿瘤的分期、分级均呈正相关,与淋巴结转移有一定关系;晚期ccRCC高表达免疫抑制分子的机制需进一步研究。 Objective:To investigate the expression of two kind of immunosuppressive molecules, nonclassical human leucocyte antigen class HLA-G and Fas ligand (FasL), in the conventional (clear cell) renal cell carcinoma (ccRCC). Methods:60 cases of ccRCCs formalin-fixed, parafflin embeded surgical specimens were examined by immunohistochemistry. The data were statistically analysed by SPSS software. Results: There was no expression of HLA-G in the normal renal tissue. HLA-G was detected in 40 ccRCC cases (66.7%) ,FasL was detected in 36 cases (60.0%). Both the HLA G and FasL were positive in 31 cases (51.7%) and were negative in 15 cases (25.0%). Both the HLA-G and FasL expression level were increased after the ccRCC cells invaded the vessel or lymphatic node. The incidence and level of HLA-G were correlated with tumor grade or stage( P〈0.01). The incidence of FasL expression were correlated with the tumor grade ( P 〈0.05)but the level of FasL expression were correlated with the tumor stage ( P 〈0.01 ). Conclasions:The expression of HLA-G and FasL were correlated with the tumor stage, grade and metastasis of ccRCC. The mechanisms of high expression of immunosuppressive mole cules in the advanced stage ccRCCs were required further investigation.
出处 《临床泌尿外科杂志》 2005年第9期567-570,573,共5页 Journal of Clinical Urology
基金 安徽省自然科学基金资助项目(No:050430704)
关键词 肾透明细胞癌 免疫抑制分子 HLA-G FAS配体 Clear cell carcinoma of kidney HLA-G FasL ligand
  • 相关文献

参考文献22

  • 1Houston A , O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Current Opinion in Pharmacology, 2004, 4 : 321 - 326.
  • 2Pinkoski M J, Green D R. Fas ligand, death gene. Cell Death and Differentiation, 1999,6: 1174-1181.
  • 3Kavurma M M, Khachigian L M. Signaling and transcriptional control of Fas ligand gene expression. Cell Death and Differentiation, 2003, 10: 36-44.
  • 4Gobin S J P,van den Elsen P J. Transcriptional regulation of the MHC class ib genes HLA-E, HLA-F, and HLA-G. Human Immunology, 2000, 61:1102-1107.
  • 5Ibrahim E C, Allory Y, Commo F.et al. Altered pattern of major histocompatibility complex expression in renal carcinoma. Tumor-Specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while Up-Regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma.Am J Pathol. 2003. 162:501-508.
  • 6Le Gal F-A. Riteau B, Sedlik C, et al. HI.A-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. International Immunology, 1999, 11:1351 -1356.
  • 7Shiroishia M. Tsumotob K. Amano K, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci,2003. 100:8856-8861.
  • 8Fournel .S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligandMediated apoptosis in activated CD81 cells by interacting with CD81. J Immunol, 2000, 164: 6100-6104.
  • 9Horuzsko A, I.enfant F, Munn D H, et al. Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice. International Immunology, 2001, 13:385-394.
  • 10Riteau B, Rouas-Freiss N, Menier C, et al. HLA-G2,-G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and Antigen-gpecific CTL cytolysis. J Immunol, 2001, 166: 5018-5026.

二级参考文献11

  • 1李宏军,俞莉章,郭应禄.Fas系统在肿瘤研究中的应用[J].中华外科杂志,1997,35(1):59-62. 被引量:30
  • 2Niehans GA,Brunner T,Frizelle SP,et al.Human lung carcinomas express Fas ligand.Cancer Res,1997,57:1007-1012.
  • 3Gratas C,Tohma Y,Barnas C,et al.Up-regulation of Fas(APO-1/CD95) ligand and down-regulation of expression in human esophageal cancer.Cancer Res,1998,58:2057-2062.
  • 4Schluter C,Dunchrow M,Wohlenberg C,et al.The cell proliferation-associated antigen of antibody Ki-67:a very large,ubiquitous nuclear protein with numerous repeated elements,representing a new kind of cell cycle-maintaining proteins. J Cell Biol,1993,123:513-522.
  • 5Haitel A,Wiener HG,Migschitz B,et al.Proliferating cell nuclear antigen and MIB-1:an alternative to classic prognostic indicators in renal cell carcinomas?Am J Clin Pathol,1997,107:229-235.
  • 6Williams N.Tumor cells fight back to beat immune system.Science,1996,274:1302-1304.
  • 7Uzzo RG,Rayman P,Kolenko V,et al.Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.Clin Cancer Res,1999,5:1219-1229.
  • 8Bukowski RM.Natural history and therapy of metastatic renal cell carcinoma:the role of interleukin-2.Cancer,1997,80:1198-1220.
  • 9郑骏年,谢叔良,陈家存,黄键.Annexin V联合PI染色法定量检测凋亡细胞[J].上海免疫学杂志,1999,19(1):31-34. 被引量:26
  • 10鲍镇美.泌尿系肿瘤[J].中华泌尿外科杂志,1999,20(9):518-520. 被引量:9

共引文献7

同被引文献28

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部